Chronicle Journal: Finance

Pharma Stocks under Review - Zoetis, Actavis, Mylan, Akorn, and VIVUS

LONDON, February 23, 2015 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Investor-Edge has initiated coverage on the following equities: Zoetis Inc. (NYSE: ZTS), Actavis PLC (NYSE: ACT), Mylan Inc. (NASDAQ: MYL), Akorn Inc. (NASDAQ: AKRX), and VIVUS Inc. (NASDAQ: VVUS). Free research report on Zoetis can be accessed at http://get.Investor-Edge.com/pdf/?c=Zoetis&d=23-Feb-2015&s=ZTS. On Friday, February 20, 2015, the NASDAQ Composite ended at 4,955.97, up 0.63%, the Dow Jones Industrial Average advanced 0.86%, to finish the day at 18,140.44, and the S&P 500 closed at 2,110.30, up 0.61%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 833.59, up 1.03%, and the index has advanced 5.63% in the previous three months. Register for your complimentary reports at the links given below.  

On Friday, shares in Zoetis Inc. recorded a trading volume of 3.71 million shares, higher than its three months average volume of 3.67 million shares. The stock ended the day at $45.60, which was 0.11% below its previous day's closing of $45.65, and registered an intraday range of $45.11 and $45.89. Shares of the company traded at a PE ratio of 32.40. Zoetis Inc.'s shares have advanced 3.05% in the last one month, 3.94% in the previous three months and 54.00% in the past one year. The stock is trading above its 50-day and 200-day moving averages of $43.63 and $37.38, respectively. Furthermore, shares of Zoetis Inc. have a Relative Strength Index (RSI) of 60.33. Sign up and read the free notes on ZTS at:

http://get.Investor-Edge.com/pdf/?c=Zoetis&d=23-Feb-2015&s=ZTS

Actavis PLC's stock gained 2.19%, to close Friday's session at $295.77, after oscillating between $289.21 and $296.77. The stock recorded a trading volume of 3.41 million shares, above its three months average volume of 2.68 million shares. Over the last one month and the previous three months, Actavis PLC's shares have advanced 7.25% and 13.87%, respectively. Additionally, the stock has gained 35.42% in the last one year. The stock is trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $269.23 is above its 200-day moving average of $238.29. Further, Actavis PLC's stock traded at a PE ratio of 106.46 and has an RSI of 69.17. The complimentary notes on ACT can be downloaded as in PDF format at:

http://get.Investor-Edge.com/pdf/?c=Actavis&d=23-Feb-2015&s=ACT

Mylan Inc.'s stock finished Friday's session 1.14% higher at $57.87. A total of 3.16 million shares were traded, which was close to its three months average volume of 3.18 million shares. The stock moved between $56.86 and $57.90 during the session. Mylan Inc.'s shares have advanced 6.01% in the last one month and 3.73% in the previous three months. Additionally, the stock has gained 11.46% in the past one year. The company's shares are trading above their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $55.37 is greater than its 200-day moving average of $51.45. Mylan Inc.'s stock traded at a PE ratio of 19.60 and has an RSI of 62.29. Register for free on Investor-Edge and access the latest research on MYL at:

http://get.Investor-Edge.com/pdf/?c=Mylan&d=23-Feb-2015&s=MYL

On Friday, shares in Akorn Inc. fluctuated between $47.44 and $48.13 before ending the session 0.19% higher at $48.02. The stock reported a trading volume of 0.81 million shares, below its three months average volume of 1.31 million shares. Shares of the company traded at a PE ratio of 166.56. Akorn Inc.'s shares have surged 14.39% in the last one month, 32.21% in the previous three months and 81.34% in the last one year. The stock is trading above its 50-day and 200-day moving averages of $41.64 and $36.54, respectively. Moreover, shares of Akorn Inc. have an RSI of 72.89. The complete research on AKRX is available for free at:

http://get.Investor-Edge.com/pdf/?c=Akorn&d=23-Feb-2015&s=AKRX

VIVUS Inc.'s stock surged 7.46%, to close the day at $2.88. The stock recorded a trading volume of 2.40 million shares, above its three months average volume of 2.09 million shares. The stock oscillated between $2.66 and $2.95 during the session. Over the last three trading sessions and over the past one year, VIVUS Inc.'s shares have declined 0.69% and 57.46%, respectively. However, the stock has advanced 5.88% in the last one month. The stock is trading above its 50-day moving average of $2.87, while the 50-day moving average is below VIVUS Inc.'s 200-day moving average of $3.91. Additionally, the stock has an RSI of 55.51. Free in depth research on VVUS is available at:

http://get.Investor-Edge.com/pdf/?c=VIVUS&d=23-Feb-2015&s=VVUS

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE Investor-Edge

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.